Hematology Oncology Edition: Top Headlines for Week of December 19, 2022

In this edition, cancer and COVID-19 increase risk for thromboembolism, glofitamab shows curative potential in lymphoma, efgartigimod improves platelet counts, and more.

Read the full coverage here:

Biomarkers predict thromboembolism risk, mortality among people with cancer, COVID-19

Glofitamab shows ‘curative potential’ in relapsed/refractory diffuse large B-cell lymphoma

Efgartigimod confers rapid improvement in platelet counts in immune thrombocytopenia

Odronextamab ‘potentially curative’ in third-line setting for follicular lymphoma

Dana-Farber professor receives William Dameshek Prize for multiple myeloma research

References:

Broome CM, et al. Abstract 3. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Hutchings M, et al. Abstract 441. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Khorana AA, et al. Abstract 136. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Kim TM, et al. Abstract 949. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Press Release